<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>NuProbe — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>54. NuProbe</h1>
    <p class="meta">Non-Invasive Cancer Diagnostics</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>NuProbe</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Wyss Institute Team</strong></p><p>Wyss Institute for Biologically Inspired Engineering at Harvard</p><p>Founded on DNA toehold probe technology developed at Wyss</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>NuProbe develops DNA toehold probe systems for non-invasive cancer diagnostics. The technology enables highly sensitive detection of circulating tumor DNA (ctDNA) in blood samples, allowing earlier cancer detection and monitoring of treatment response without invasive biopsies.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series A</strong> — Raised venture funding to advance product development and clinical validation.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute spinout company portfolio and liquid biopsy technology coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Growing liquid biopsy market:</strong> Non-invasive cancer testing is projected to exceed $10B by 2030.</li><li><strong>Technical differentiation:</strong> Toehold probe technology offers unique sensitivity advantages.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Competitive landscape:</strong> Grail, Guardant, and Foundation Medicine dominate liquid biopsy.</li><li><strong>Reimbursement challenges:</strong> Payer coverage for liquid biopsy still inconsistent.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What cancer types does your platform detect most effectively?</li><li>How does your sensitivity compare to existing liquid biopsy platforms?</li><li>What is your clinical validation strategy and timeline?</li><li>Are you targeting screening, diagnosis, or treatment monitoring?</li><li>How do you plan to achieve Medicare and commercial payer coverage?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
